Physician profile
Delean Lunger
NPI 1962566158
$1,690.09
in general payments reported to CMS, 2019-2025
13 companies · $556 in 2025
The $556 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $540 · 2024: $408 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.65 | 2023-2025 | |
| Neurelis, INC. | $188.35 | 2024 | Valtoco |
| Madrigal Pharmaceuticals | $136.27 | 2025 | Rezdiffra |
| Silk Road Medical, INC. | $127.28 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Genzyme Corporation | $122.24 | 2023 | |
| Astellas Pharma US INC | $112.12 | 2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $108.53 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $104.55 | 2022 | |
| Alnylam Pharmaceuticals INC. | $97.85 | 2025 | Amvuttra |
| Abiomed | $92.15 | 2024 | Impella |
| Novo Nordisk INC | $89.77 | 2023 | |
| Braeburn INC. | $87.90 | 2025 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $82.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delean Lunger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.